Evidence map›Paper›PMID 40481955›Full record

ArticleLasers in medical science2025

Comparative evaluation of palliative holmium laser enucleation and plasma kinetic prostate resection in the management of advanced prostate cancer with lower urinary tract symptoms.

Kun Xu, Qian Su, Jiadong Xu, Lei Qiu, Yong Zhang, Donghua Gu, Jiangang Chen, Zhibo Gu

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Lasers in medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Kun Xu *Department of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China.
Qian Su *Department of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China.
Jiadong XuDepartment of Urology, The Third Hospital of Nantong University, Nantong, China.
Lei QiuDepartment of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China.
Yong ZhangDepartment of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China.
Donghua GuDepartment of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China.
Jiangang ChenDepartment of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China. jiangang_chenc1@126.com.
Zhibo GuDepartment of Urology, Nantong First Peoplpe's Hospital. Affiliated Hospital 2 of Nantong University, Nantong, China. guzhibob_g@126.com.

Funding

Medical Research Project of Nantong Health Commission MS2024032Nantong First People's Hospital High-Level Science and Technology Project Cultivation Fund YPYJJYB24008Nantong Science and Technology Bureau General Project MSZ2024032
6 · The paper itself

Abstract

This study aimed to evaluate the efficacy of palliative holmium laser enucleation of the prostate (HoLEP) versus plasma kinetic resection of the prostate (PKRP) in the management of advanced prostate cancer (APC) with concurrent lower urinary tract symptoms (LUTS).A retrospective analysis was conducted from February 2017 to March 2021, which included 41 patients with LUTS from two centers. Of these, 23 patients underwent palliative HoLEP and 18 underwent PKRP. Variables including age, prostate-specific antigen (PSA), prostate volume (V), Gleason Score, clinical staging, International Prostate Symptom Score (IPSS), maximum urinary flow rate (Qmax), functional outcomes, and postoperative complications at 3, 6, and 12 months were compared. Kaplan-Meier survival curves were utilized to analyze overall survival (OS) and progression-free survival (PFS) in both groups, and a Cox proportional hazards regression model was employed to identify risk factors for mortality.Baseline characteristics were comparable between the two groups (p > 0.05). Both groups showed significant improvements in IPSS, Qmax, and post-void residual (PVR) were observed compared to baseline, with HoLEP showing greater enucleation efficiency and a significant improvement in Qmax. After one year of follow-up, the HoLEP group demonstrated a 96.0% reduction in PSA levels (from 84.5 to 3.4 ng/mL). Five patients required electrocoagulation for bleeding, but no Clavien Dindo IV complication, such as rectal injury, were reported. Kaplan-Meier analysis revealed that the 3-year PFS rates for the HoLEP and PKRP groups were 82.6% and 72.2%, respectively, with median survival times of 29.1 months (95% CI: 26.59 to 30.40) and 28.0 months (95% CI: 18.90 to 37.1). No statistically significant differences were found in OS (HR = 1.071, p = 0.884) and PFS (HR = 0.956, p = 0.907) between the groups. Cox regression analysis identified age (HR = 0.833; 95% CI: 0.749-0.928), clinical staging (HR = 0.336; 95% CI: 0.133-0.999), and Gleason Score (HR = 0.456; 95% CI: 0.217-0.958) as predictive risk factors for OS. For patients with APC and concurrent LUTS who are unresponsive to androgen deprivation therapy (ADT), surgical intervention such as palliative holmium laser enucleation and plasma kinetic prostate resection may be considered to temporarily relieve symptoms such as bladder outlet obstruction (BOO) and persistent hematuria.

Indexed as

Lasers, Solid-StateLaser TherapyLower Urinary Tract SymptomsPalliative CareProstatectomyProstatic NeoplasmsAgedAged, 80 and overHumansMaleMiddle AgedRetrospective StudiesAdvanced prostate cancerHoLEPLUTSOSPFSPlasma kinetic resection of the prostate

Identifiers

PMID40481955

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.